Report Date: Thursday, July 23, 2026, before market open · Call: 8:30 a.m. ET
Quest Diagnostics has been on a strong run heading into this report. Shares are up roughly 24.5% year-to-date and trade near their 52-week high (~$207-216 range in July vs. a 52-week range of $165.78–$219.20), reflecting three consecutive quarters of accelerating growth, guidance raises, and margin expansion. Sell-side sentiment has firmed alongside the stock — Baird raised its price target to $236 on July 13 while maintaining a Neutral/Hold rating, and the broader analyst base is split roughly evenly between Buy and Hold ratings, suggesting expectations are now fairly high.
Quest has beaten Zacks consensus EPS estimates in each of the trailing four quarters, with an average surprise around 3.5%, including a 5.49% beat last quarter. That said, consensus estimates have drifted down slightly over the past 90 days (from ~$2.87 to ~$2.81-2.82), signaling some caution about the magnitude of the beat this time given tougher comps and known cost headwinds in the back half of the year.
Quest's Q1 was a blowout that reset the trajectory for the year. Revenue grew 9.2% to $2.90 billion with 9.0% organic growth, and adjusted diluted EPS rose 13.1% to $2.50. Management subsequently raised full-year 2026 guidance: revenue to $11.78–$11.90 billion (from $11.70–$11.82 billion) and adjusted EPS to $10.63–$10.83 (from $10.50–$10.70).
Key Q1 dynamics that investors will be watching for continuation: - Total requisition volume grew 10.9% (organic +10.8%), with Fresenius Medical Care and Corewell Health contributing approximately 7 points of that growth. Excluding those two relationships, organic volume growth was still a healthy 3.8%. - Revenue per requisition was down 1.3% headline, but up 2.5% excluding the Fresenius/Corewell mix effect, driven by richer test-per-requisition mix (Advanced Diagnostics, consumer testing). - Consumer channel (questhealth.com plus wellness/wearables partnerships) grew strongly, with questhealth.com direct growth in the "high 20s%" and partnership-driven growth even faster. - Advanced Diagnostics — especially the AD-Detect Alzheimer's blood-test franchise — delivered double-digit growth, with management noting the Alzheimer's testing book more than doubled year-over-year.
1. Corewell Health & Fresenius Medical Care ramp. These two relationships remain the single biggest swing factor for reported growth and mix. Management guided to roughly a $250 million full-year revenue contribution from Corewell and an incremental $80–$100 million from Fresenius, together adding about 3.3 points to full-year revenue growth. Watch for confirmation these tracking in line, and commentary on the new southeast Michigan JV lab (targeted to open in 2027) and Fresenius's expansion beyond its own dialysis clinics into independent providers.
2. Margin phasing / cost headwinds shifting into H2. Management flagged that the cadence of earnings this year should run "just over 49%" of revenue/EPS in H1 and "just over 50%" in H2 — a reversal from last year's pattern — driven by: (a) Project Nova technology-transformation spend, expected to be ~$0.25 of full-year EPS dilution with over 60% of that expense loaded into H2; (b) elevated fuel costs (~$7–10 million, ~$0.05–0.07 of EPS) embedded for the balance of the year; and (c) a tougher weather comp, since summer/hurricane-season weather in 2025 was unusually mild and 2026 assumes a more normal (negative) impact. Investors should listen for whether these costs are tracking as planned or creating incremental pressure.
3. Consumer/wellness momentum durability. The consumer channel (direct-to-consumer plus wearable/wellness partnerships) has been a standout growth and margin contributor — management has noted the margin profile there is "on par, if not slightly better" than the enterprise average given its cash-pay, low-complexity nature. Any deceleration or acceleration here, plus updates on new partnerships, will be closely watched, as will commentary on the competitive landscape (e.g., Function Health's acquisition of home-draw company Getlabs).
4. Advanced Diagnostics pipeline — Haystack MRD, oncology, brain health. Watch for updates on Haystack MRD commercial ramp and reimbursement progress (PLA pricing of ~$3,900 baseline/$800 monitoring, MolDX submission for Medicare Advantage), the new Guardant Shield colorectal-cancer blood-collection partnership, and continued double-digit growth in cardiometabolic/endocrine and Alzheimer's testing.
5. Regulatory/policy overhangs. Two items feature prominently: (a) the PAMA data reporting cycle (survey period running through roughly end of July) and the RESULTS Act, which if passed would freeze Medicare lab rates at current levels — management characterized progress as encouraging but noted timing risk from summer recess and midterm election dynamics; and (b) the CMS "CRUSH" RFI on lab fraud/waste/abuse, which management has downplayed as having minimal direct exposure for Quest (the tests driving the flagged Medicare spend increase were largely proprietary PLA codes and molecular/genetic tests outside Quest's core mix). Also watch for any updates on ACA subsidy expiration impacts — management has embedded a conservative 30bps revenue headwind assumption but had seen no negative impact through Q1.
6. Capital allocation and M&A. Quest raised its quarterly dividend 7.5% to $0.86/share with Q4 results and continues to repurchase stock (2.5 million shares for $452 million in 2025, with ~$0.4 billion remaining under authorization as of year-end). Management has characterized the M&A funnel (health-system outreach deals, potential Co-Lab collaborations, independent lab acquisitions) as healthy, though guidance excludes any contribution from prospective M&A, leaving upside optionality if deals close.
| Metric | Updated Guidance (Low–High) |
|---|---|
| Net revenue | $11.78B – $11.90B (+6.8% to +7.8%) |
| Reported diluted EPS | $9.58 – $9.78 |
| Adjusted diluted EPS | $10.63 – $10.83 |
| Cash from operations | ~$1.75B |
| Capital expenditures | ~$550M |
Given the Q1 beat-and-raise pattern and continued momentum flagged qualitatively through the quarter, a further guidance increase alongside the Q2 print is plausible, but investors should weigh that possibility against the known H2 cost step-up (Nova, fuel, weather) that management has explicitly built into the back half.
Quest heads into Q2 with genuine business momentum — broad-based organic growth across physician, hospital, and consumer channels, accretive strategic partnerships (Corewell, Fresenius), and a fast-growing, higher-margin consumer/advanced-diagnostics mix — but also a stock that has already re-rated meaningfully (near 52-week highs, ~22-23x trailing earnings) and a consensus bar that assumes continued high-single-digit revenue growth and mid-single-digit-plus EPS beats. The read-through from peers has been mixed this earnings season (e.g., Danaher's sharp post-earnings decline on a soft growth outlook), so investors will want to hear management reaffirm both the top-line algorithm (ex-Fresenius/Corewell organic growth, test-per-requisition mix) and the phasing of H2 cost headwinds before extrapolating the Q1 beat-and-raise into the back half of the year.